Symbiosis launches multi-million pound sterile drug manufacturing capability in Scotland

Symbiosis launches multi-million pound sterile drug manufacturing capability in Scotland

Symbiosis Pharmaceutical Services Limited, an MHRA-approved sterile manufacturing facility based in Stirling, Scotland is an exciting, young company specializing in the small-scale manufacture of sterile pharmaceuticals for clinical trials (fill/finish). Symbiosis has successfully completed clinical trial manufacturing projects with clients from across Europe and Asia, including Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) and Encap Drug Delivery. The UK Government regulator, the MHRA, recently granted Symbiosis an MIA (IMP) license, allowing the company to manufacture sterile liquid, lyophilized, conventional, cytotoxic and biological drugs for biotechnology company clients around the world.
Colin MacKay, founder and Chief Executive of Symbiosis said: "Symbiosis is proud to have built, qualified and licensed its new manufacturing facility within a matter of months, achieving a timeline never seen before in the industry. Equally, Symbiosis has built an outstanding team of people who are passionate about delivering a level of client service which not only exceed clients' expectations but which is delivered in the shortest timeframe that the biopharmaceutical industry has ever seen. This reflects the demands of our target market for flexible, responsive and time-focussed manufacturing service excellence. 

"We have an outstanding track record of helping our clients meet their clinical trial deadlines. This increases the value of that particular pharmaceutical asset, which in turn increases the probability of the client successfully raising crucial further investment.
"Our intention is to be both the fastest, and the best, small-scale sterile fill/finish company in the world."
Symbiosis' manufacturing facility was designed and built with a clear understanding of its clients' needs in mind. Two state-of-the-art manufacturing suites, one of which is capable of handling cytotoxic and highly potent pharmaceuticals, have been built with integrated, industry-leading, Restricted Access Barrier System (RABS) technology – ensuring Symbiosis is at the leading edge of compliance with emerging regulatory requirements while ensuring clients have enhanced sterility assurance during the manufacture of their pharmaceutical product.

While Symbiosis specialises in phase I and phase II GMP (Good Manufacturing Practice) manufacture of liquid, lyophilized, conventional, cytotoxic and biological drugs, it also provides a range of closely associated services; analytical testing, clinical labelling and packaging, Qualified Person release and controlled temperature storage and shipment.
Symbiosis was founded in 2011 in Stirling, Scotland and comprises a team of 17 highly experienced people. The company's core focus is delivering service excellence and reducing client drug development timelines, founded on a comprehensive and value-adding technical and quality skills base. It is a world-class Contract Manufacturing Organisation (CMO) with a highly experienced management team with decades of collective sterile fill/finish experience.
To find out more please visit www.symbiosis-pharma.com

Call Dr John Porter on +44 (0)7703 194 351 or email [email protected].

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.